Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPA1 | P27694 | 11/20 | 0.46 |
| ▸ | PPP1CA | P62136 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2319966 | 0.80 | PPP1CA (0.68) | RPA1PPP1CAL3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL14696670 | 0.80 | RPA1 (0.53) | RPA1PPP1CAL3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL2318841 | 0.78 | RPA1 (0.68) | RPA1PPP1CAL3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL1143854 | 0.77 | RPA1 (0.67) | RPA1PPP1CAL3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL30912707 | 0.75 | KMT2A (0.42) | RPA1PPP1CAL3MBTL1SMN1; SMN2KMT2A | |
| SCHEMBL2319936 | 0.75 | RPA1 (0.54) | RPA1PPP1CAL3MBTL1SMN1; SMN2KMT2A | |
| SCHEMBL14995361 | 0.75 | PPP1CA (0.71) | RPA1PPP1CAL3MBTL1SMN1; SMN2KMT2A | |
| SCHEMBL15004255 | 0.75 | KMT2A (0.56) | RPA1PPP1CAL3MBTL1SMN1; SMN2KMT2A | |
| SCHEMBL29271151 | 0.74 | APOBEC3A (0.47) | RPA1PPP1CAL3MBTL1SMN1; SMN2ALDH1A1 | |
| SCHEMBL15004322 | 0.73 | KMT2A (0.51) | RPA1PPP1CAL3MBTL1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140128616-A1 | OXYGEN-SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-05-08 | — | — | US | disclosed |
| US-8664257-B2 | Oxygen-substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals | SANOFI (FR) | 2014-03-04 | — | — | US | disclosed |
| US-20130046004-A1 | OXYGEN-SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2013-02-21 | — | — | US | disclosed |
| EP-2528902-A1 | OXYGEN-SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2012-12-05 | — | — | EP | disclosed |
| WO-2011092187-A1 | OXYGEN-SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130046004-A1 | OXYGEN-SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | CTSF, CTSS, CTSE | RPA1 4448/4885PPP1CA 4330/4885L3MBTL1 2784/4885 |
| US-20140128616-A1 | OXYGEN-SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | CTSF, CTSS, CTSE | RPA1 4448/4885PPP1CA 4330/4885L3MBTL1 2784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.